Length of Study for Participants Sample Clauses

Length of Study for Participants. You will be in this study for about 44 days. This does not include the time between screening and dosing, which can be up to 28 days. This part of the study involves: • 1 dosing period during 1 continuous admission • 18 overnight stays at the CRU. You will not be able to leave the CRU during that time • 1 follow-up visit about 7 days after the last dose • 1 follow-up phone call about 4 weeks after the last dose
Sample 1Sample 2
AutoNDA by SimpleDocs
Length of Study for Participants. If you are in Group 1 or 2, you will be in this study for about 64 days. If you are in the Japanese dosing group (if done), you will be in this study for about 37 days. If you are in Group 4, you will be in this study for about 51 days. This does not include the time between screening and dosing, which can be up to 28 days. This part of the study involves: • Dosing groups 1 and 2 have 4 dosing periods with 2 separate admissions. Each admission has up to 11 overnight stays at the Clinical Research Unit (CRU). You will not be able to leave the CRU during the 2 admission periods o A Japanese dosing group, if done, will have 2 dosing periods during 1 continuous admission with 11 overnight stays o Dosing group 4 has 4 dosing periods during 1 continuous admission with up to 25 overnight stays • 1 follow-up visit to the CRU about 7 days after the last dose • 1 follow-up phone call about 4 weeks after the last dose There will be about 7 days between each dose. However this may be changed based on emerging data.
Sample 1Sample 2
Length of Study for Participants. You will be in this study for about 58 days in Part 1, about 46 days in Part 2, and about 41 days in Part 3. This does not include the time between screening and dosing, which can be up to 28 days. This study involves: Part 1: • 2 to 4 dosing periods during 1 continuous admission • 11 to 25 overnight stays at the Clinical Research Unit (CRU). You will not be able to leave the CRU during that time • 1 follow-up phone call about 4 weeks after the last dose of study drug There will be at least 5 days between each dose. Part 2: • 1 dosing period during 1 continuous admission, receiving multiple doses every day for 10 days in a row • 12 overnight stays at the CRU. You will not be able to leave the CRU during that time • 1 follow-up phone call about 4 weeks after the last dose of study drug Part 3 (if done): • 3 dosing periods during 1 continuous admission • 7 overnight stays at the CRU. You will not be able to leave the CRU during that time • 1 follow-up phone call about 4 weeks after the last dose of study drug There will be at least 2 days between each dose. Eligibility to Participate in Another Drug Study Your eligibility to take part in another study depends on information from this study. You may be eligible to receive a different study drug in another study as soon as 30 days after your last dose of study drug in this study. This is true for most drugs. Some drugs may stay in your body longer which means that you may have to wait longer before joining another study. These results are usually known after your last blood sample is tested. We will tell you this as soon as possible. We will also tell you if there is a longer than usual period of time that you should not be in another drug study after this one. Our goal is to keep you from doing anything that might potentially harm you. Dosing Plan The dose of the study drug that will be used to treat people is not yet known. Part 1 (single, increasing dose) Two groups of participants are planned for this part of the study. There will be up to 6 participants in each of these groups. The dosing is planned as follows: Dosing Periods Group Number of Participants Period 1 Period 2 Period 3* Period 4* 1 2 A C E TBD** 2 A C E TBD** 2 A C E TBD** 2 2 B D F TBD** 2 B D F TBD** 2 B D F TBD** *Dosing Periods 3 and 4 may not be needed ** To be determined Treatment A: 150 mg study drug or placebo Treatment B: 500 mg study drug or placebo Treatment C: 1500 mg study drug or placebo Treatment D: 3000 mg study drug or placebo...
Sample 1
Length of Study for Participants. Dosing Sequence 1 You will be in this study for about 49 days. This does not include the time between screening and dosing, which can be up to 28 days. This part of the study involves: • 3 dosing periods during 1 continuous admission. • 23 overnight stays at the CRU. You will not be able to leave the CRU during that time • 1 follow-up visit to the CRU about 7 days after the last dose • 1 follow-up phone call about 4 weeks after the last dose There will be at least 10 days between dosing in Period 1 and Period 2, and at least 7 days between dosing in Period 2 and Period 3. Dosing Sequence 2 You will be in this study for about 44 days. This does not include the time between screening and dosing, which can be up to 28 days. This part of the study involves: • 3 dosing periods during 1 continuous admission • 18 overnight stays at the CRU. You will not be able to leave the CRU during that time • 1 follow-up visit to the CRU about 7 days after the last dose • 1 follow-up phone call about 4 weeks after the last dose There will be at least 7 days between each dose.
Sample 1

Related to Length of Study for Participants

  • Admission and Enrollment of Students For a student to be accepted and enrolled into a dual credit program, the STUDENT shall:

  • Number of Students 6.2.2.1.1 Except as herein provided, Instructors shall have at any time no more than an average of thirty-five (35) students per instructional section, averaged over all instructional sections assigned to the instructor.

  • Special Enrollment Under the circumstances described below, referred to as “qualifying events”, eligible employees and/or eligible dependents may request to enroll in the Plan outside of the initial and annual open enrollment periods, during a special enrollment period.

  • Evaluation of Students Acknowledging the District’s adopted grading system, the teacher shall maintain the right and responsibility to determine grades and other evaluation of a student. No grade or evaluation shall be changed except by the teacher with the approval of the building administrator.

  • Form B - Contractor’s Annual Employment Report Throughout the term of the Contract by May 15th of each year the Contractor agrees to report the following information to the State Agency awarding the Contract, or if the Contractor has provided Contract Employees pursuant to an OGS centralized Contract, such report must be made to the State Agency purchasing from such Contract. For each covered consultant Contract in effect at any time between the preceding April 1st through March 31st fiscal year or for the period of time such Contract was in effect during such prior State fiscal year Contractor reports the:

  • SALARY DETERMINATION FOR EMPLOYEES IN ADULT EDUCATION PCA Article B.3 does not apply in School District No. 34 (Abbotsford).

  • Maternity Benefits (i) Subject to the provisions of this part of the Agreement a female contributor who-

  • Salary Progression 1. For the purposes of determining annual progression from one step to the next, each teacher’s performance will be assessed annually against the appropriate professional standards.

  • Initial Enrollment Upon retirement, each new retiree who is eligible to enroll in plans under the Health Benefits Program shall receive uninterrupted coverage under the plan in which he or she was enrolled as an active employee, provided the employee submits all necessary applications and other required documentation in a timely fashion.

  • Overtime for Part-Time Employees (a) A part-time employee working less than the normal hours per day of a full-time employee, and who is required to work longer than their regular workday, shall be paid at the rate of straight-time for the hours so worked, up to and including the normal hours in the workday of a full-time employee.

Time is Money Join Law Insider Premium to draft better contracts faster.